BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer
(2018)
Journal Article
Purpose: Adjuvant tamoxifen treatment revolutionized the management of estrogen receptor (ER) positive breast cancers to prevent cancer recurrence; however drug resistance compromises its clinical efficacy. The mechanisms underlying tamoxifen resista... Read More about BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer.